A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial-Reference-Cited by-同舟云学术

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Published:2015-05 Issue:5 Volume:26 Page:921-927
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fuchs C.S.,Azevedo S.,Okusaka T.,Van Laethem J.-L.,Lipton L.R.,Riess H.,Szczylik C.,Moore M.J.,Peeters M.,Bodoky G.,Ikeda M.,Melichar B.,Nemecek R.,Ohkawa S.,Świeboda-Sadlej A.,Tjulandin S.A.,Van Cutsem E.,Loberg R.,Haddad V.,Gansert J.L.,Bach B.A.,Carrato A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/5/921/16699315/mdv027.pdf

Reference28 articles.

1. SEER Stat Fact Sheets: Pancreas Cancer. National Cancer Institute. http://seer.cancer.gov/statfacts/html/pancreas.html (3 March 2014, date last accessed).

2. Trends in the treatment and outcome of pancreatic cancer in the United States;Baxter;Ann Surg Oncol,2007

3. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma;Tempero;J Clin Oncol,2003

4. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma v.1.2014,2014

5. ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Seufferlein;Ann Oncol,2012

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic plasma small extracellular vesicles miRNA signatures for pancreatic cancer using machine learning methods;Translational Oncology;2024-02

2. Therapeutic Monoclonal Antibodies against Cancer: Present and Future;Cells;2023-12-14

3. Signalling in pancreatic cancer: from pathways to therapy;Journal of Drug Targeting;2023-10-26

4. IGF-1R targeting in cancer – does sub-cellular localization matter?;Journal of Experimental & Clinical Cancer Research;2023-10-20

5. Molecular imaging of pancreatic ductal adenocarcinoma;VIEW;2023-07-11